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would be desirable. Consequently, identification of pre-
dictors of the expansion of small AAAs may become
important for managing this type of patient with regard to
operative intervention or other therapies and may also
help to explain the pathogenesis of AAA.
The levels of elastase have been found elevated in the cir-
culation and aneurysmal walls compared with those with
aortic occlusive atherosclerosis.7-9 Furthermore, circulating
levels of Cystatin C B, the major inhibitor of cysteine pro-
teases, have been reported decreased in aneurysmal cases
compared with a sex-matched and age-matched control
group.10 Finally, the levels of various metallodependent pro-
teases (MMPs), especially MMP2 and MMP9, have been
found elevated in aneurysmal aortic walls compared with
aortic walls of occlusive atherosclerosis,11,12 and we have
earlier reported a positive significant correlation between the
plasma level of MMP9 and the expansion of small AAAs.13
Besides its fibrinolytic function in plasma, plasmin also
seems to play a central role in the activation of the degener-
ative processes in tissues. It is capable of degrading extracel-
lular matrix directly—the extracellular matrix degradation
produced by infiltrating macrophages depends upon pres-
ence of plasmin—and it produces active MMPs by cleaving
the latent pro-MMPs.14,15 Furthermore, it has been mea-
sured in high concentrations in aneurysmal walls compared
with those of controls.16 Thus, plasmin could be involved in
the pathogenesis of AAA. Plasmin is immediately inactivated
in blood by antiplasmin forming plasmin-antiplasmin-com-
plexes (PAPs)17. After 5 years of screening and surveillance
The UK Small Aneurysm Trial1 randomized 4-cm to
5.5-cm abdominal aortic aneurysms (AAAs) to early
surgery or watchful waiting and could not show any dif-
ference in AAA-specific mortality between the two groups.
However, no matter what AAA size is used as indication
for operation, the dilemma of occasional rupture of small
AAA, and some operated AAA never would have ruptured
if they were left without surgery.1-4 Furthermore, increas-
ing use of ultrasound scanning and computed tomography
scanning have increased the number of small AAAs diag-
nosed. A number of these will expand to operation-rec-
ommendable AAA size, but the patients will then be older
with increased risk at operation or will have developed a
contraindication for operation. Finally, conservative treat-
ment of such small AAAs has been shown to create psy-
chologic stress among the patients.5,6 These problems will
certainly increase if screening for AAA proves to be bene-
ficial6. Therefore, a more specific indication for operation
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Objective: Three proteolytic systems seem involved in the aneurysmal degradation of the aortic wall. Plasmin is a com-
mon activator of the systems and could thus be predictive for the progression of abdominal aortic aneurysms (AAAs).
Methods and Materials: In 1994, 112 of 141 male patients with AAA diagnosed through population screening (defined
as 3 cm or more) were interviewed and examined and had blood samples taken. One hundred twelve cases were scanned
annually for 1 to 5 years (mean, 2.5 years) and referred for surgery if the AAA exceeded 5 cm in diameter. A random
sample of 70 of the 112 cases had P-plasmin-antiplasmin-complexes (PAPs), P-plasminogen, and S-elastin-peptides
(SEPs).
Results: PAP was positively correlated with annual expansion rate (r = 0.39, 0.16-0.56), persisting after adjustment for
initial AAA size, SEP, age, and smoking. However, PAP levels did not correlate with the initial AAA size or SEP.
Furthermore, PAP levels were significantly predictive for cases expanding to operation-recommendable AAA sizes.
Combined with the initial AAA size, both optimal sensitivity and specificity were 82%, increasing to 95% and 96%,
respectively, excluding those lost to follow-up and accepting 2 mm of interobserver variation.
Conclusion: The progression of AAA is correlated with the PAP level, which seems to have a predictive value similar to
the best serologic predictor known, serum-elastin-peptides. (J Vasc Surg 2001;34:611-5.)
of small AAAs, we have tried to assess whether the plasma
concentrations of PAP are correlated with aneurysmal
expansion and predictive for cases expanding to operation-
recommendable sizes in a cohort of male patients diagnosed
through ultrasound scan screening.
MATERIALS AND METHODS
In 1994, half (4404) of all 65-year-old to 73-year-old
men in Viborg county, Denmark, were invited to B-mode
ultrasound scan screening for AAA at their regional hospi-
tal. Their mean age was 68.5 ± 2.68 years. Of these, 3344
(76%) attended. An AAA was defined as a maximal aortic
diameter of 30 mm or more, and an AAA was diagnosed
in 141 (4.2%) respondents. They were informed, inter-
viewed, and examined, including undergoing a repeat
ultrasound scan, by the doctor of the trial.
Blood samples were taken by the nurse and doctor of
the trial to handle each sample in a strictly standardized
manner. Serum samples were left for coagulation at 18°C
for 45 minutes, while the plasma samples were stabilized
with ethylenediamine tetraacetic acid. Centrifugation
started 45 minutes after sampling. The samples were
frozen at –21°C until analysis.
Of the 141 diagnosed AAAs, 19 were larger than 5 cm
in diameter at diagnosis and were referred for surgery; the
remaining 122 (87%) cases were offered annual control
scans and referred for surgery if the AAA expanded to
larger than 5 cm in maximal AAA size.
Of these, ten were lost to follow-up during the first year,
mainly because of severe illness or death. Consequently, 112
cases were followed for 1 to 5 years (mean, 2.5 years).
Because of limited economical resources, a random
sample of 70 of the 112 small AAAs was selected for PAP
analysis with the randomization utility in EPI-info 6
(USD, Inc, Ga) Their mean age was 69.4 ± 2.74 years;
their mean AAA size was 35.7 ± 5.36 mm; and 56% were
smokers. After 5 years, 24 of these 70 cases had been
referred for surgery, and 8 were lost to follow-up within 5
years because of development of severe illness or death.
None had surgery performed because of symptomatic
AAA.
P-PAP and P-plasminogen were determined using the
commercial assay available from Dade Behring (Marburgh,
Germany). The intra-assay and interassay coefficients of
variation were 2% to 6% and 3% to 11%, respectively. The
principle method was a sandwich enzyme immunoassay
with specific monoclonal antibodies for the in vitro deter-
mination of PAP and plasminogen in human plasma.
The concentration of elastin peptides in serum was
determined using an inhibition type of enzyme-linked
immuno-sorbent assay performed as we have described
earlier,18 and essentially as that described by Giro and
Davidson.19 The intra-assay and interassay coefficients of
variation were 6% and 10%, respectively.
Concerning the anterior-posterior (AP) aortic diameter,
the interobserver correlation coefficient between the two
observers in 50 blinded double measurements was 0.98, the
mean difference was 0.1 ± 0.84 mm (P = .88), the variabil-
ity was 1.68 mm, the arithmetic mean of difference was
0.42 ± 0.73mm, and the arithmetic variability was 1.46
mm.20 The variation of the transverse measurements was
larger concerning all of these end points. Consequently, AP
diameters were used for follow-up measurements.
Expansion was calculated as the change in the AP
diameter during the whole observation period trans-
formed to annual units. It was on average 3.1 mm/year ±
2.1, ranging from 0 to 0.5 mm per year. The mean over-
all change in AP diameter during the observation period
was 8.5 mm ± 5.3 mm. Thus, 91.2% expanded more than
the variability of the measurement.
The trial was approved by the local scientific ethics com-
mittee and reported to the Central Control of Registers.
Statistical methods. The statistical software package
used was SPSS 10.0 (SPSS, Inc, Chicago, Ill). A simple
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Fig 1. A, Scatter plot concerning concentration of plasma PAPs
and annual expansion rate of small AAAs (Pearson correlation
coefficient, r = 0.39; 95% CI, 0.16-0.56). B, Scatterplot con-
cerning concentration of plasma PAPs and initial size of AAAs
(Pearson correlation coefficient, r = 0.18; 95% CI, –0.07-0.41).
A
B
P-plasmin-antiplasmin-complexes (µmol/L)
P-plasmin-antiplasmin-complexes (µmol/L)
scatter plot with Pearson product moment correlation was
initially used to give a visual and quantitative impression of
the association between PAP, initial AAA size, and expan-
sion rate.21
Hereafter, multiple linear regression analysis using the
expansion rate as the dependent variable was performed to
adjust for potential confounders and to create a predictive
formula concerning the predicted annual expansion rate as
follows: predicted annual expansion rate (mm/year) =
bPAP (PAP) + bsize (initial AAA size) + a (constant). The
predicted expansion during 5 years was then calculated by
multiplying the predicted annual expansion rate by 5, and
the predictive AAA size after 5 years was then calculated
by adding it to the initial AAA size. The predictive AAA
size after 5 years was then used in a receiver-operating
characteristic (ROC) curve.21 The curve is constructed by
finding the sensitivity and specificity for the predicted
AAA size after 5 years using patients on whom surgery was
performed as true positives, and patients on whom it was
not as false positives.
The ROC curve analyses were performed to test the
predictive value of the tests concerning predicting cases
expanding to operation-recommendable sizes. For analysis
of the ROC curves, the null hypothesis was that the test
had a performance similar to the diagonal line, ie, the area
under the curve was 0.5. If the lowest 95% confidence
limit for the area under the curve was more than 0.5, a sig-
nificant predictive test was said to be present.
RESULTS
The median concentration of PAP was 369 ± 160
µmol/L, whereas the manufacturer states that the refer-
ence median concentration in healthy adult donors is 290
± 295 µmol/L.
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The level of PAP was positively correlated with expan-
sion rate (r = 0.39; 95% CI, 0.16-0.56; P < .001), persist-
ing after adjustment for initial AAA size, age, S-elastin-
peptides (SEPs), and smoking (Fig 1, A). PAP levels were
not significantly correlated with initial AAA size, but a
trend was noticed. A larger sample size might have shown
a significant correlation. (r = 0.17; 95% CI, –0.07-0.41; 
P = .16) (Fig 1, B). However, SEP did not show a trend
of correlation with PAP (r = 0.04; P = .77). Nevertheless,
SEPs were positively correlated with the mean annual
expansion rate (r = 0.31; 95% CI, 0.11-0.48). No associ-
ation between plasminogen and expansion rate or initial
AAA size was noticed.
PAP levels continued to be significantly associated
with expansion in a multiple linear regression analysis
using initial AAA size as the independent variable with the
formula of the predicted annual expansion rate (mm/year)
= 0.238 (initial AAA size [mm]) + 0.002379 (PAP) –
6.23.
After 5 years, 24 of the 70 cases were referred for pre-
operative evaluation. The PAP levels were significantly
predictive for cases expanding to operation-recommend-
able AAA sizes (area under ROC curve = 65%; 95% CI,
0.51%-0.80%) with an optimal sensitivity and specificity of
65% and 67%, respectively (Fig 2).
If PAP was combined with initial AAA size, the opti-
mal sensitivity and specificity were both 83%, compared
with 77% and 66%, respectively, if initial AAA size was
used alone.
The similar ROC curves are shown in Fig 3 when 2
mm of variation in the measurements are accepted. The
optimal sensitivity and specificity both increased to 90%
concerning PAP combined with initial AAA size, com-
pared with 81% for both if initial AAA size was used alone.
Fig 2. ROC curves for predicting cases expanding to operation-
recommendable AAA size concerning SEPs, plasma PAPs, initial
AAA size, and PAP combined with initial AAA size (PAP + initial
AAA size).
Fig 3. ROC curves for predicting cases expanding to operation-
recommendable AAA size with acceptance of 2-mm interobserver
variation concerning SEPs, plasma PAPs, initial AAA size, and
PAP combined with initial AAA size (PAP + initial AAA size).
Eight were lost to follow-up within 5 years because of
development of severe illness or death. None underwent
surgery because of symptomatic AAA. If they were
excluded and 2-mm interobserver variation was accepted,
the optimal sensitivity and specificity both increased to
95% concerning PAP combined with initial AAA size,
compared with 91% and 92%, respectively, if initial AAA
size alone was used (Fig 4).
DISCUSSION
The study has demonstrated, for the first time, a sig-
nificant correlation between PAP and the expansion rate
of small AAA persisting after adjustment for initial AAA
size, age, SEP, and smoking. Additional adjusting variables
were not included in the multivariate analysis because we
have been unable to show certain other risk factors of
expansion, except antibodies against Chlamydia pneumo-
niae and MMP9 after researching atherosclerotic diseases,
hypertension, pulmonary diseases, systemic and ankle
blood pressures, pulmonary function, cholesterol, low-
density–lipoprotein cholesterol, high-density–lipoprotein
cholesterol, triglycerides, oxidized low-density lipopro-
tein, lipoprotein A, and homocysteine, among others.22-27
PAP alone was shown to have an optimal sensitivity
and specificity of 65% and 67%, respectively, in predicting
cases expanding to operation-recommendable sizes.
Apparently, a sensitivity and specificity of about 66% con-
cerning PAP in predicting future operation seems clinically
useless. However, the individual prediction must clearly
take into account how close the AAA is from its goal (size
of operation indication). Our results suggest a potential
clinically useful predictive tool based on PAP combined
with the initial AAA size in decision making in the man-
agement of small AAAs because of a sensitivity and a speci-
ficity of 82%, both increasing to 95% by accepting 2 mm
of interobserver variation in the measurements and
excluding patients lost to follow-up. By adding PAP into
the prediction, the predictive values increased by 5% to
10% compared with initial AAA size alone.
Thus, PAP levels in combination with initial AAA size
seem to have the potential to be a clinically reliable pre-
dictor of the natural history of AAA. Currently, the best
serologic predictor of aneurysmal expansion is SEP. We
have earlier reported a correlation coefficient of 0.40 con-
cerning SEP and expansion rate,18 whereas the correlation
coefficient between PAP and expansion rate was 0.39 in
this study. We have also earlier reported the 5-year predic-
tive values of SEP and procollagen-III-N-terminal
propeptide for cases expanding to operation-recommend-
able sizes as a sensitivity and specificity of 91% and 94%,
respectively,27 whereas the similar values of PAP were both
95% in this study. Consequently, despite the potential pol-
lution with PAP originating from nonaortic locations, 
the correlation between PAP and the natural history of
small AAA is one of the strongest serologic associations
reported.
However, some questions need to be answered before
clinical application of the predictive tool can be recom-
mended. First, the numbers are relatively small with conse-
quently relative large CIs. Second, our observed
interobserver variation of 1.68 mm seems smaller than that
of most other studies,20,28-32 and furthermore, the same
scanner was used for all the measurements. Consequently,
the predictive values could be overestimated compared
with a situation where the model is generalized. Third, it
also seems relevant to question whether the prediction of
90% to 95% of all AAAs that will undergo surgery within 5
years is sufficiently satisfactory, because 5% to 10% of the
operations would have to be carried out in patients with
AAAs that would not reach 5 cm in diameter within 5 years
or in patients who will be lost to follow-up mainly because
of death or severe illness. However, a larger amount of
patients lost to follow-up because of severe illness or death
may have a high frequency of contraindications for surgery.
Furthermore, the risk of rupture is removed, their quality
of life is normalized, the operation could probably be per-
formed at lower risk because of a lower age, and the pre-
dictive tool may reduce the psychologic consequences
concerning those that are not predicted to be recommend-
able for surgery. However, the operation is potentially
lethal (4%-7%), and the risk of rupture is limited in small
AAA (0.25%-0.5% annually), but only a relatively small
amount of additional operations (approximately 5%-10%)
would be needed. Carrying out the operations earlier could
reduce the operative mortality and morbidity more than
the additional procedures will produce and thus reduce the
overall physical, psychologic, and economical costs. The
model suggests 5% to 10% more operations, but if the
surgery is carried out earlier, when the patients are more
fit, complications and operative mortality may be reduced
by more than 10%.
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Fig 4. ROC curves for predicting cases expanding to operation-
recommendable AAA size with acceptance of 2-mm interobserver
variation and exclusion of cases lost to follow-up within the first
5 years concerning SEPs, plasma PAPs, initial AAA size, and PAP
combined with initial AAA size (PAP + initial AAA size).
In all, the model needs to be validated in a prospective
and possibly randomized study involving a larger number
of AAAs, both sexes, and several observers and scanners to
analyze the cost effectiveness of using the model before it
can be clinically recommended.
CONCLUSION
The progression of AAA seems to be correlated with
the level of PAP, a known activator of the described pro-
teases involved in the aneurysmal matrix degradation. In
all, the level of PAP in aneurysmal cases seems to have a
similar or better predictive value of the natural history of
AAA compared with what is currently the best serological
predictor known, SEPs.
The nurse of the trial, Anette Sahlholdt, and Dr Per
Jaeger and Skive Sygehus are thanked for excellent and
committed practical and administrative support.
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